1 week Ago By Defense World Staff
Prudential Financial Inc. acquired a new stake in Zura Bio Limited (NASDAQ:ZURA – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 11,105 shares of the company’s stock, valued at approximately $28,000.
Several other hedge funds and other institutional investors have also made changes to their positions in the company. Geode Capital Management LLC lifted its stake in Zura Bio by 70.6% in the third quarter.
Geode Capital Management LLC now owns 912,625 shares of the company’s stock valued at $3,706,000 after acquiring an additional 377,545 shares during the last quarter. Barclays PLC lifted its stake in Zura Bio by 777.1% in the 3rd quarter.
Barclays PLC now owns 64,061 shares of the company’s stock valued at $260,000 after purchasing an additional 56,757 shares during the last quarter. Rhumbline Advisers grew its holdings in Zura Bio by 37.3% during the fourth quarter.
Rhumbline Advisers now owns 37,657 shares of the company’s stock worth $94,000 after purchasing an additional 10,231 shares during the period. The Manufacturers Life Insurance Company acquired a new position in Zura Bio during the third quarter worth approximately $71,000. Finally, State Street Corp raised its stake in Zura Bio by 47.
5% in the third quarter. State Street Corp now owns 395,059 shares of the company’s stock valued at $1,604,000 after buying an additional 127,300 shares during the period. 61.
14% of the stock is owned by institutional investors. Zura Bio Price PerformanceZURA stock opened at $1.21 on Friday.
The business’s fifty day moving average price is $1.32 and its two-hundred day moving average price is $2.50.
The stock has a market capitalization of $82.73 million, a price-to-earnings ratio of -2.28 and a beta of 0.
08. Zura Bio Limited has a fifty-two week low of $0.97 and a fifty-two week high of $6.
35. Zura Bio (NASDAQ:ZURA – Get Free Report) last issued its quarterly earnings data on Tuesday, March 25th. The company reported ($0.
08) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.09.
The business had revenue of $0.00 million during the quarter. Research analysts expect that Zura Bio Limited will post -0.
65 EPS for the current year. Analyst Upgrades and DowngradesSeveral brokerages have recently commented on ZURA. Guggenheim reiterated a “buy” rating and set a $15.
00 target price on shares of Zura Bio in a research note on Wednesday, March 26th. Chardan Capital reduced their price objective on shares of Zura Bio from $12.00 to $10.
00 and set a “buy” rating for the company in a research report on Wednesday, March 26th. Oppenheimer reissued an “outperform” rating and issued a $19.00 price objective (down from $20.
00) on shares of Zura Bio in a research report on Wednesday, March 26th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Zura Bio in a report on Thursday, April 3rd. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock.
According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $14.67.Get Our Latest Analysis on Zura BioZura Bio Profile (Free Report)Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders.
It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.Read MoreFive stocks we like better than Zura BioWhen to Sell a Stock for Profit or LossJPMorgan is a Buy, if You Can Handle The Volatility Consumer Staples Stocks, ExplainedUnited States Steel’s Crash: An Unmissable Buying OpportunityWhat Does a Stock Split Mean? Rocket Lab Stock: Weathering the Storm, Time for a Comeback?.
